Cogent Biosciences (COGT) reported updated results Monday from the open-label extension portion of the SUMMIT clinical trial evaluating bezuclastinib in patients with nonadvanced systemic mastocytosis.
The biotech firm said the clinical results focus on 27 patients in the open-label extension who were treated with the once-daily 100 mg dose of bezuclastinib.
Cogent said that at 24 weeks of treatment, 31% of patients had reduced or discontinued best supportive care medications. It also said Bezuclastinib "showed rapid, deep, and sustained reductions" in serum tryptase during 24 weeks of treatment.
Shares of Cogent Biosciences were down 19% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。